[TC-DC] The use of autologous Thrombo-Cytes for induction of Dendritic Cell activity
Invention
The therapeutic use of dendritic cells in vaccination approaches requires prior activation of these immune cells. The invention exploits the power of stimulated thrombocytes to activate dendritic cells ex vivo thereby offering the unique opportunity of autologous activation Commercial opportunity Immune therapy with activated dendritic cells is a well established methodology used for various indications and also for cancer vaccination strategies. Therefore the market potential is enormous. The technology offered is the first autologous one to mature dendritic cells into potent antigen presenting cells capable of optimal induction of T-cell responses. The simple and efficient activation strategy is strikingly simple to handle and compatible to established immunotherapy protocols. Current status An EU patent for TC-DC claiming priority from a German national application has been filed with the European Patent Office in March 2003. The European Patent has been granted in October 2006. It is being validated in Switzerland, Germany, France, Great Brittain and Italy. On behalf of the University Duisburg-Essen, PRO-vendis offers licences for TC-DC, options for their analysis and the opportunity for further co-development.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Recovering phosphorus from sewage sludge ash
Chemical and heat treatment of sewage sludge can recover phosphorus in a process that could help address the problem of diminishing supplies of phosphorus ores. Valuable supplies of phosphorus could…
Efficient, sustainable and cost-effective hybrid energy storage system for modern power grids
EU project HyFlow: Over three years of research, the consortium of the EU project HyFlow has successfully developed a highly efficient, sustainable, and cost-effective hybrid energy storage system (HESS) that…
After 25 years, researchers uncover genetic cause of rare neurological disease
Some families call it a trial of faith. Others just call it a curse. The progressive neurological disease known as spinocerebellar ataxia 4 (SCA4) is a rare condition, but its…